Dacomitinib: first global approval

M Shirley - Drugs, 2018 - Springer
Dacomitinib (Vizimpro®) is an orally administered, small-molecule irreversible inhibitor of
HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid …
被引用次数：100 相关文章

Dacomitinib: First Global Approval

M Shirley - Drugs, 2018 - search.proquest.com
Dacomitinib (Vizimpro®) is an orally administered, small-molecule irreversible inhibitor of
HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid …

Dacomitinib: First Global Approval

M Shirley - Drugs, 2018 - pubmed.ncbi.nlm.nih.gov
Dacomitinib (Vizimpro®) is an orally administered, small-molecule irreversible inhibitor of
HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid …

Dacomitinib: First Global Approval.

M Shirley - Drugs, 2018 - search.ebscohost.com
Abstract Dacomitinib (Vizimpro< sup>®</sup>) is an orally administered, small-molecule
irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for …

Dacomitinib: First Global Approval.

M Shirley - Drugs, 2018 - europepmc.org
Dacomitinib (Vizimpro®) is an orally administered, small-molecule irreversible inhibitor of
HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid …